Literature DB >> 8377506

Serum and immunohistochemical studies of NCC-ST-439 in breast cancer.

T Narita1, H Funahashi, Y Satoh, T Imai, H Takagi.   

Abstract

It has been thought that NCC-ST-439 antigen (ST-439) is a tumor-related carbohydrate antigen. The authors conducted serum and immunohistochemical studies to investigate the clinical significance of ST-439 in breast cancer. The level of serum ST-439 was elevated in advanced and recurrent breast cancers. In comparison with CEA and CA15-3, ST-439 was superior in sensitivity but inferior in specificity to these markers. The level of serum ST-439 showed no correlation with the levels of CEA or CA15-3. In the combination assay of these three markers, 80.6% of recurrent cases and 33.8% of primary cases were positive. Immunohistochemically, the expression of ST-439 was observed in 28.1% of noncancerous mammary duct epithelium and in 38.1% of the cancerous portion. From the above, we concluded that ST-439 was a tumor-related antigen and could be a tumor marker with high sensitivity in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8377506     DOI: 10.1002/jso.2930540104

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  A Case of Breast Cancer Metastatic to the Pituitary Gland.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.

Authors:  Kan Yonemori; Noriyuki Katsumata; Ayako Noda; Hajime Uno; Mayu Yunokawa; Eriko Nakano; Tsutomu Kouno; Chikako Shimizu; Masashi Ando; Kenji Tamura; Masahiro Takeuchi; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-05       Impact factor: 4.553

Review 3.  Extralobar pulmonary sequestration with elevated serum neuron-specific enolase: A case report and review of the literature.

Authors:  Feng-Wei Kong; Wei-Min Wang; Longbo Gong; Wenbin Wu; Miao Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.